Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Seeking Alpha
IMRX's combination nearly doubles standard-of-care 12-month OS (64% vs. 35%), with a favorable safety profile and regulatory alignment for phase 3 initiation mid-2026. Market overreacted to the OS decline from 9 to 12 months; cross-trial comparisons are misleading and do not reflect the differentiated mechanism of IMRX's MEK inhibitor. IMRX is well capitalized through 2029, with upcoming catalysts including expanded phase 2a data [H1 2026] and phase 3 MAPKeeper 301 trial data [2028]. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Jacob Wackerhausen/iStock via Getty Images The last time I spoke about Immuneering Corporation ( IMRX ) it was in a Seeking Alpha article entitled "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst." With respect to this article, I mentioned that More on my IG service This article is published by Terry Chri
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]Yahoo! Finance
- Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]Yahoo! Finance
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPGlobeNewswire
- Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]Seeking Alpha
- Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]Yahoo! Finance
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 1/16/26 - Form 4
- 1/15/26 - Form SCHEDULE
- 1/15/26 - Form 4
- IMRX's page on the SEC website